306 related articles for article (PubMed ID: 37500645)
1. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications.
Jiang Y; Shen X; Zhi F; Wen Z; Gao Y; Xu J; Yang B; Bai Y
Cell Death Discov; 2023 Jul; 9(1):266. PubMed ID: 37500645
[TBL] [Abstract][Full Text] [Related]
2. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
3. Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia.
Haybar H; Shahrabi S; Rezaeeyan H; Jodat H; Saki N
J Cell Physiol; 2019 Sep; 234(9):14500-14506. PubMed ID: 30770558
[TBL] [Abstract][Full Text] [Related]
4. Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.
Mozdarani H; Asghari F
Arch Iran Med; 2010 Jan; 13(1):26-33. PubMed ID: 20039766
[TBL] [Abstract][Full Text] [Related]
5. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
7. Arsenic-induced apoptosis in malignant cells in vitro.
Akao Y; Yamada H; Nakagawa Y
Leuk Lymphoma; 2000 Mar; 37(1-2):53-63. PubMed ID: 10721769
[TBL] [Abstract][Full Text] [Related]
8. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
9. Studies on curative efficacy of monoterpene eugenol on anti- leukemic drug arsenic trioxide induced cardiotoxicity.
Binu P; Priya N; Abhilash S; Vineetha RC; Nair RH
Biomed Pharmacother; 2017 Jul; 91():559-566. PubMed ID: 28494415
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract][Full Text] [Related]
12. Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide.
Borges GSM; Sicard P; de Mello Gomides Loures C; Evangelista FGC; Sales CC; de Paula Sabino A; Fernandes C; Ferreira LAM; Richard S
AAPS PharmSciTech; 2023 Mar; 24(3):79. PubMed ID: 36918482
[TBL] [Abstract][Full Text] [Related]
13. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
15. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Sönksen M; Kerl K; Bunzen H
Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
[TBL] [Abstract][Full Text] [Related]
16. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
[TBL] [Abstract][Full Text] [Related]
17. [Research advances on effect of arsenic trioxide on tumor].
Feng CQ; Ma WL; Zheng WL
Ai Zheng; 2002 Dec; 21(12):1386-9. PubMed ID: 12520754
[TBL] [Abstract][Full Text] [Related]
18. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
19. Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.
Yedjou CG; Moore P; Tchounwou PB
Int J Environ Res Public Health; 2006 Jun; 3(2):136-40. PubMed ID: 16823087
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells.
Tsai CW; Chang NW; Tsai RY; Wang RF; Hsu CM; Lin SS; Wu CN; Sun SS; Tsai MH; Bau DT
Anticancer Res; 2010 Sep; 30(9):3655-60. PubMed ID: 20944150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
